PD-L2 is a second ligand for PD-1 and inhibits T cell activation-Reference-Cited by-同舟云学术

PD-L2 is a second ligand for PD-1 and inhibits T cell activation

Published:2001-03 Issue:3 Volume:2 Page:261-268
ISSN:1529-2908
Container-title:Nature Immunology
language:en
Short-container-title:Nat Immunol

Author:

Latchman Yvette,Wood Clive R.,Chernova Tatyana,Chaudhary Divya,Borde Madhuri,Chernova Irene,Iwai Yoshiko,Long Andrew J.,Brown Julia A.,Nunes Raquel,Greenfield Edward A.,Bourque Karen,Boussiotis Vassiliki A.,Carter Laura L.,Carreno Beatriz M.,Malenkovich Nelly,Nishimura Hiroyuki,Okazaki Taku,Honjo Tasuku,Sharpe Arlene H.,Freeman Gordon J.

Publisher

Springer Science and Business Media LLC

Subject

Immunology,Immunology and Allergy

Link

http://www.nature.com/articles/ni0301_261.pdf

Reference24 articles.

1. McAdam, A. J., Schweitzer, A. N. & Sharpe, A. H. The role of B7 co-stimulation in activation and differentiation of CD4+ and CD8+ T cells>. Immunol. Rev. 165, 231–247 (1998).

2. Thompson, C. B. & Allison, J. P. The emerging role of CTLA-4 as an immune attenuator. Immunity 7, 445–450 (1997).

3. Tivol, E. A. et al. Loss of CTLA-4 leads to massive lymphoproliferation and fatal multiorgan tissue destruction, revealing a critical negative regulatory role of CTLA–4. Immunity 3, 541–547 (1995).

4. Waterhouse, P. et al. Lymphoproliferative disorders with early lethality in mice deficient in Ctla-4. Science 270, 985–988 (1995).

5. Chambers, C. A., Sullivan, T. J. & Allison, J. P. Lymphoproliferation in CTLA-4-deficient mice is mediated by costimulation-dependent activation of CD4+ T cells. Immunity 7, 885–895 (1997).

Cited by 2444 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. References;The Evolution of Immunotherapy Against Tumors;2025

2. PD-L1 and PD-1 in immune regulation and their implications in blood cancers;Advances in Cancer Biology - Metastasis;2024-10

3. Prognostic Protein Biomarker Screening for Thyroid Carcinoma Based on Cancer Proteomics Profiles;Biomedicines;2024-09-10

4. Cell Identity and Spatial Distribution of PD‐1/PD‐L1 Blockade Responders;Advanced Science;2024-09-09

5. Immune checkpoint inhibitors in infectious disease;Immunological Reviews;2024-09-09